Research Analysts Issue Forecasts for Humana FY2025 Earnings

Humana Inc. (NYSE:HUMFree Report) – Equities research analysts at Cantor Fitzgerald issued their FY2025 earnings per share estimates for shares of Humana in a research report issued to clients and investors on Tuesday, January 21st. Cantor Fitzgerald analyst S. James forecasts that the insurance provider will earn $16.17 per share for the year. Cantor Fitzgerald has a “Neutral” rating and a $395.00 price objective on the stock. The consensus estimate for Humana’s current full-year earnings is $16.11 per share.

Humana (NYSE:HUMGet Free Report) last released its earnings results on Wednesday, October 30th. The insurance provider reported $4.16 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.48 by $0.68. The firm had revenue of $29.30 billion during the quarter, compared to analysts’ expectations of $28.66 billion. Humana had a return on equity of 13.20% and a net margin of 1.18%.

Several other brokerages have also recently weighed in on HUM. Wells Fargo & Company decreased their price objective on Humana from $387.00 to $290.00 and set an “overweight” rating for the company in a report on Monday, November 4th. Morgan Stanley raised their price objective on Humana from $288.00 to $301.00 and gave the company an “equal weight” rating in a report on Tuesday, December 17th. TD Cowen raised their price objective on Humana from $261.00 to $268.00 and gave the company a “hold” rating in a report on Monday, November 4th. Jefferies Financial Group downgraded shares of Humana from a “buy” rating to a “hold” rating and cut their target price for the company from $519.00 to $253.00 in a research note on Monday, October 7th. Finally, Sanford C. Bernstein upgraded shares of Humana from a “market perform” rating to an “outperform” rating and set a $308.00 target price for the company in a research note on Tuesday, October 8th. Twenty analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $302.80.

View Our Latest Research Report on HUM

Humana Price Performance

Shares of NYSE HUM opened at $284.93 on Wednesday. The stock has a market capitalization of $34.31 billion, a price-to-earnings ratio of 25.24, a PEG ratio of 2.13 and a beta of 0.55. The business has a 50-day moving average of $273.91 and a 200-day moving average of $306.03. The company has a debt-to-equity ratio of 0.67, a current ratio of 1.76 and a quick ratio of 1.76. Humana has a fifty-two week low of $213.31 and a fifty-two week high of $411.80.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. State Street Corp grew its stake in shares of Humana by 1.0% during the third quarter. State Street Corp now owns 5,357,420 shares of the insurance provider’s stock worth $1,701,582,000 after buying an additional 53,272 shares during the last quarter. FMR LLC grew its stake in shares of Humana by 23.4% during the third quarter. FMR LLC now owns 3,388,859 shares of the insurance provider’s stock worth $1,073,387,000 after buying an additional 643,291 shares during the last quarter. Pzena Investment Management LLC lifted its holdings in shares of Humana by 8.1% during the third quarter. Pzena Investment Management LLC now owns 2,506,250 shares of the insurance provider’s stock worth $793,830,000 after purchasing an additional 187,903 shares during the period. Marshall Wace LLP lifted its holdings in shares of Humana by 118.9% during the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock worth $532,564,000 after purchasing an additional 774,085 shares during the period. Finally, Legal & General Group Plc lifted its holdings in shares of Humana by 2.1% during the second quarter. Legal & General Group Plc now owns 1,183,985 shares of the insurance provider’s stock worth $442,396,000 after purchasing an additional 24,842 shares during the period. 92.38% of the stock is owned by institutional investors.

Insider Activity

In related news, insider Timothy S. Huval sold 3,703 shares of Humana stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $256.26, for a total value of $948,930.78. Following the transaction, the insider now directly owns 8,181 shares of the company’s stock, valued at $2,096,463.06. This trade represents a 31.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. 0.29% of the stock is owned by company insiders.

Humana Company Profile

(Get Free Report)

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

Featured Stories

Earnings History and Estimates for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.